Full Press Release Details
Therapeutics to Launch MyoCorrect Orofacial Myofunctional Therapy Service
to offer MyoCorrect via telemedicine for all Vivos-trained clinicians to use as therapeutic protocol in tandem with the Vivos
RANCH, Colo., March 30, 2021 - Vivos Therapeutics, Inc. (the "Company" or "Vivos") (NASDAQ: VVOS),
a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered
breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that it will launch a new service called
MyoCorrect, where trained therapists will provide Vivos-trained providers access to orofacial myofunctional therapy
(OMT) via telemedicine technology as a component to OSA treatment using the Company's Vivos System.
expects to see additional revenue from its new MyoCorrect service in the form of increased Vivos System cases and fees charged
for the service. Vivos believes the MyoCorrect service will become an important value-added component in the treatment of OSA
using the Vivos System. Vivos further believes that offering OMT as a service will provide Vivos with an additional competitive
advantage in the OSA treatment marketplace.
therapists work to strengthen and improve function in the muscles of the lips, tongue, cheeks and face and their related roles
in breathing, sucking, chewing, swallowing, and some aspects of speech. Research has shown OMT to be an effective component of
OSA treatment. Vivos plans to make the MyoCorrect protocol available as a component of the Vivos System and will actively integrate
training and implementation protocols for Vivos trained dentists to utilize the MyoCorrect therapy.
dentists who have actively incorporated OMT into their Vivos System treatment protocols report four primary benefits: (1) higher
case acceptance, (2) better patient compliance, (3) shorter treatment times, and (4) improved clinical outcomes. However, due
to scarcity of trained OMT therapists in many areas and other factors, too few dentists and patients have been able to access
this important adjunctive therapy. MyoCorrect will provide every Vivos dentist with immediate and easy access via telemedicine
to this valuable clinical resource at an attractive price point.
launch of this new service is an important step for Vivos as we continue to offer what we believe are the best therapeutic options
available for patients who suffer from sleep disordered breathing and the most prevalent forms of obstructive sleep apnea. We
believe we will be able to leverage our current infrastructure and growing dentist network for rapid deployment and adoption of
the MyoCorrect OMT therapy," said Kirk Huntsman, Vivos' Chairman and CEO. "As Vivos- trained dentists come to
experience the ways in which OMT can enhance their Vivos System case outcomes, we expect the adoption rate of MyoCorrect as an
integral part of the Vivos System to rise. As that happens, the revenue contributions of MyoCorrect to Vivos in the form of increased
Vivos System sales as well as fees charged for the OMT service could be significant."
look forward to rolling out MyoCorrect across our network in the coming months," continued Huntsman. "We believe this
clinical enhancement to our flagship Vivos System treatment for mild-to-moderate OSA will work synergistically within the emerging
Vivos dental sleep medicine ecosystem. This ecosystem features extensive clinical training through the Institute for Craniofacial
Sleep Medicine, Vivos AireO2 practice management software, Vivos Airway Intelligence Services, Vivos Billing Intelligence Services,
VivoScore diagnostic devices powered by SleepImage, our proprietary Vivos System oral appliance therapy, and multi-disciplinary
collaboration between physicians and Vivos dentists through the growing network of Vivos-trained dentist offices and Pneusomnia
launch of MyoCorrect follows the acquisition by Vivos of certain assets from and the entry into related agreements with MyoCorrect,
LLC and its affiliates. MyoCorrect, LLC is a healthcare provider based in New York that specializes in the delivery of OMT via
Vivos Therapeutics, Inc.
Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative treatments
for adult patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA) that are
provided through appropriately licensed providers. The Vivos treatment for mild-to-moderate OSA involves customized oral appliances
and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically
effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos
oral appliances have proven effective in over 15,000 patients treated worldwide by more than 1,200 trained dentists. Combining
technologies and protocols that alter the size, shape and position of the tissues of a patient's upper airway, the Vivos
System opens airway space and significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System
has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with mild-to-moderate
OSA. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using
more information, visit www.vivoslife.com.
Note Regarding Forward-Looking Statements
press release and the statements of the Company's management made in connection therewith contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such
as "may", "should", "expects", "intends", "plans", "believes",
"anticipates", "hopes", "estimates" and variations of such words and similar expressions are
intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number
of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond
Vivos' control. Actual results (including the results of the Company's new OMT service described herein and its impact
on the Company's results of operations) may differ materially from those expressed or implied by such forward-looking statements.
Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos'
filings with the Securities and Exchange Commission ("SEC"). Vivos' filings can be obtained free of charge on
the SEC's website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking
to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos'
expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Kasunich / Jenny Robles
Strategic Communications
896-1241 / (212) 896-1231